INmune Bio Inc. to Report Third Quarter 2024 Financial Results and Provide Corporate Update on October 31, 2024
INmune Bio (NASDAQ: INMB) has announced it will host a conference call on October 31, 2024, at 4:30 PM EDT to discuss its third quarter 2024 financial results and provide a corporate update. The clinical-stage inflammation and immunology company, which focuses on microglial activation and neuroinflammation in Alzheimer's Disease, will make the call available via phone and webcast. A transcript will be provided approximately 24 hours after the call, and a replay will be accessible through November 7, 2024.
INmune Bio (NASDAQ: INMB) ha annunciato che terrà una conference call il 31 ottobre 2024 alle 16:30 EDT per discutere i risultati finanziari del terzo trimestre 2024 e fornire un aggiornamento aziendale. L'azienda, attiva nella fase clinica, si concentra sull'attivazione microgliale e sulla neuroinfiammazione nella malattia di Alzheimer e renderà la chiamata disponibile tramite telefono e webcast. Una trascrizione sarà fornita circa 24 ore dopo la chiamata, e una registrazione sarà accessibile fino al 7 novembre 2024.
INmune Bio (NASDAQ: INMB) ha anunciado que realizará una conferencia telefónica el 31 de octubre de 2024 a las 4:30 PM EDT para discutir sus resultados financieros del tercer trimestre de 2024 y proporcionar una actualización corporativa. La empresa en etapa clínica, que se centra en la activación microglial y la neuroinflamación en la enfermedad de Alzheimer, hará la llamada disponible a través de teléfono y webcast. Se proporcionará una transcripción aproximadamente 24 horas después de la llamada, y una repetición estará accesible hasta el 7 de noviembre de 2024.
INmune Bio (NASDAQ: INMB)는 2024년 10월 31일 오후 4시 30분 EDT에 2024년 3분기 재무 결과를 논의하고 회사 업데이트를 제공하는 컨퍼런스 콜을 개최한다고 발표했습니다. 알츠하이머병의 미세아교세포 활성화와 신경염증에 중점을 둔 임상 단계 회사는 전화를 통해 그리고 웹캐스트로 콜을 제공할 것입니다. 콜 후 약 24시간 후에 문자 기록이 제공되며, 2024년 11월 7일까지 재생이 가능합니다.
INmune Bio (NASDAQ: INMB) a annoncé qu'il tiendra une conférence téléphonique le 31 octobre 2024 à 16h30 EDT pour discuter de ses résultats financiers du troisième trimestre 2024 et fournir une mise à jour de l'entreprise. L'entreprise, qui se trouve en phase clinique et se concentre sur l'activation microgliale et la neuroinflammation dans la maladie d'Alzheimer, proposera l'appel par téléphone et en webcast. Un compte rendu sera fourni environ 24 heures après l'appel, et un replay sera accessible jusqu'au 7 novembre 2024.
INmune Bio (NASDAQ: INMB) hat bekannt gegeben, dass am 31. Oktober 2024 um 16:30 Uhr EDT eine Telefonkonferenz stattfinden wird, um die finanziellen Ergebnisse des 3. Quartals 2024 zu besprechen und ein Unternehmensupdate zu geben. Das Unternehmen, das sich in der klinischen Phase befindet und sich auf die Aktivierung von Mikroglia und Neuroinflammation bei Alzheimer konzentriert, wird die Konferenz sowohl telefonisch als auch über Webcast verfügbar machen. Ein Transkript wird etwa 24 Stunden nach dem Anruf bereitgestellt, und eine Wiederholung ist bis zum 7. November 2024 zugänglich.
- None.
- None.
Management to host conference call and webcast at 4:30 pm ET on that day
Boca Raton, Florida, Oct. 24, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s Disease (AD), today announced that it will host a conference call on Thursday October 31, 2024, at 4:30pm EDT to discuss results for its quarter ended September 30, 2024 and to provide a corporate update.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio Third Quarter Conference Call when reaching the operator.
Date: October 31, 2024
Time: 4:30 PM Eastern Time
Participant Dial-in: 1-800-343-4136 Participant Dial-in (international): 1-203-518-9843
Conference ID: INMUNE
A live audio webcast of the call can be accessed by clicking here or using this link:
https://viavid.webcasts.com/starthere.jsp?ei=1692115&tp_key=9ac4a06029
A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through November 7, 2024 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 11157233.
About INmune Bio Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. XPRO, the first of several DN-TNF products, is in clinical trials to determine if it can treat patients with Mild Alzheimer’s disease. Additional therapeutic indications including treatment-resistant depression and oncology will be pursued when resources allow. The Natural Killer Cell Priming Platform includes INKmune™, a therapy developed to prime a patient’s NK cells to treat patients with cancer. INKmune uses a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies. The INKmune trial is enrolling patients into a US Phase I/II trial in men with metastatic castrate resistant prostate cancer. To learn more, please visit www.inmunebio.com.
Forward Looking Statements
Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595, and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
INmune Bio Contact:
David Moss, CFO (858) 964-3720
info@inmunebio.com
Investor Contact:
Mike Moyer
Managing Director – LifeSci Advisors
mmoyer@lifesciadvisors.com
FAQ
When will INmune Bio (INMB) report Q3 2024 earnings?
How can investors access INmune Bio's (INMB) Q3 2024 earnings call?
Until when will INmune Bio's (INMB) Q3 2024 earnings call replay be available?
